Purpose
|
LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.
|
Characteristics
|
Target: BACE inhibitor,Beta amyloid inhibitor, Gamma-secretase Receptor: BACE1, Beta Amyloid, Gamma-secretase
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
99.80?%
|
Formula
|
C15H14F2N4S
|
Solubility
|
10 mM in DMSO and 200 mM in ethanol
|